Ganirelix

被引：22

作者：

Gillies, PS ^{[1
]}

Faulds, D ^{[1
]}

Balfour, JAB ^{[1
]}

Perry, CM ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland 10, New Zealand

来源：

DRUGS | 2000年 / 59卷 / 01期

关键词：

D O I：

10.2165/00003495-200059010-00007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Ganirelix is a synthetic third generation gonadotropin-releasing hormone (GnRH) antagonist that is administered via the subcutaneous route. The drug competitively blocks GnRH receptors in the anterior pituitary gland, preventing endogenous GnRH from inducing luteinising hormone (LH) and follicle stimulating hormone release. Ganirelix effectively inhibited LH surges during controlled ovarian stimulation in a large, multicentre clinical trial in women undergoing in vitro fertilisation. A vital pregnancy rate per embryo transfer of 40.3% was achieved at weeks 5 to 6 after treatment with the 0.25 mg/day dosage. Subcutaneous ganirelix has been generally well tolerated in clinical trials. The most common adverse events were local injection site events, asthenia, nausea, malaise, headache and fatigue.

引用

收藏

页码：107 / 111

页数：5

相关论文

共 14 条

[1] High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization [J].

de Jong, D ;

Macklon, NS ;

Mannaerts, BMJL ;

Bennink, HJTC ;

Fauser, BCJM .

HUMAN REPRODUCTION, 1998, 13 (03) :573-575

[2] CONTROL OF THE PREOVULATORY LUTEINIZING-HORMONE SURGE BY GONADOTROPIN-RELEASING-HORMONE ANTAGONISTS - PROSPECTS FOR CLINICAL-APPLICATION [J].

FRASER, HM ;

BOUCHARD, P .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1994, 5 (02) :87-93

[3] GONADOTROPIN-RELEASING-HORMONE AND ITS ANALOGS - FROM LABORATORY TO BEDSIDE [J].

HENZL, MR .

CLINICAL OBSTETRICS AND GYNECOLOGY, 1993, 36 (03) :617-635

[4] GnRH agonists and antagonists in ovarian stimulation [J].

Hodgen, G .

HUMAN REPRODUCTION, 1996, 11 :123-132

[5] First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) [J].

Itskovitz-Eldor, J ;

Kol, S ;

Mannaerts, B ;

Bennink, HC .

HUMAN REPRODUCTION, 1998, 13 (02) :294-295

[6]

LONNING PE, 1993, CANCER SURV, V17, P343

[7]

Mannaerts B, 1998, HUM REPROD, V13, P3023

[8] SUPPRESSION OF FOLLICULAR PHASE PITUITARY-GONADAL FUNCTION BY A POTENT NEW GONADOTROPIN-RELEASING-HORMONE ANTAGONIST WITH REDUCED HISTAMINE-RELEASING PROPERTIES (GANIRELIX) [J].

NELSON, LR ;

FUJIMOTO, VY ;

JAFFE, RB ;

MONROE, SE .

FERTILITY AND STERILITY, 1995, 63 (05) :963-969

[9] Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran*).: Part I.: Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers [J].

Oberyé, JJL ;

Mannaerts, BMJL ;

Kleijn, HJ ;

Timmer, CJ .

FERTILITY AND STERILITY, 1999, 72 (06) :1001-1005

[10] Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran*).: Part II.: Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers [J].

Oberyé, JJL ;

Mannaerts, BMJL ;

Huisman, JAM ;

Timmer, CJ .

FERTILITY AND STERILITY, 1999, 72 (06) :1006-1012